Dr. Werner Lanthaler is a distinguished biotechnology executive and strategic investor who has dedicated his career to advancing life sciences innovation. As Founder and CEO of WLanholding GmbH, he focuses on investments and advisory services in Life Science and high-tech sustainability companies.
His portfolio includes transformative companies like Proxygen GmbH, Cerabyte GmbH, Solgate GmbH, Planet Pure GmbH, and Cyment. With over two decades of leadership experience, Werner previously transformed Evotec SE from a 200-employee company to a global leader with over 5,000 employees and revenues growing from €40 million to €800 million.
His expertise spans drug discovery innovation, AI integration in biotechnology, and building strategic partnerships that drive scientific breakthroughs. Werner combines deep industry knowledge with a commitment to sustainable innovation, positioning him as a catalyst for the next generation of life sciences advancement.
Before joining Evotec, Werner served as Chief Financial Officer at Intercell AG, where he played a pivotal role in creating Austria's inaugural venture-capital-funded biotechnology enterprise. During his tenure, he successfully guided the company through its groundbreaking public offering, marking a historic milestone as the first Austrian biotech firm to achieve IPO status, while simultaneously managing the worldwide commercialization of their Japanese Encephalitis vaccine.
